Since enhanced CD8+ T cell memory responses by mTOR inhibition is independent of IL-15 [32, 33], rapamycin-treated CD8 T cells should retain the ability to respond to the survival signaling provided by IL-15, which may explain why IL-15 and rapamycin can act synergistically to improve the survival and antitumor responses of tumor antigen-specific CD8+ T cells. Here, MTOR is linked to neoplasm.